A Phase 2 Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Participants With Indolent Non-Hodgkin Lymphoma

Seoul National University Bundang Hospital, Seongnam-si

IEO - Istituto Europeo di Oncologia, IRCCS, Milan

Ospedale di Circolo, PO Varese, AO Ospedale di Circolo e Fondazione Macchi, Varese

Mid-Florida Cancer Centers, Orange City

Florida Cancer Specialists - Fort Myers, Fort Myers

Florida Cancer Specialists & Research Institute - Lecanto, Lecanto

Tennessee Oncology, Nashville

AUSL di Reggio Emilia IRCCS, Arcispedale Santa Maria Nuova di Reggio Emilia, Reggio Emilia

Oncology Istituto Romagnolo per lo Studio dei Tumori (IRST) Dino Amadori, Meldola

Universitaetsklinikum Bonn AöR, Bonn

Robert H. Lurie Comprehensive Cancer Center, Chicago

Comprehensive Cancer Centers of Nevada, Las Vegas

"State Budgetary Healthcare Institution of Moscow City Moscow Multidisciplinary Clinical Center Kommunarka of the Department of Healthcare of Moscow City", Moscow

City Clinical Hospital n.a. Botkin, Moscow

First Saint-Petersburg State Medical University n.a. I.P. Pavlov, Saint Petersburg

FN Hradec Kralove, Hradec Králové

Vseobecna fakultni nemocnice v Praze, Prague

Azienda Ospedaliera Santa Maria di Terni, Terni

Wojewodzki Szpital Specjalistyczny im. Janusza Korczaka w Slupsku Sp. z o.o., Słupsk

Pratia Onkologia Katowice, Katowice

Centrum Medyczne Pratia Poznan, Skórzewo

Seoul National University Hospital, Seoul

Severance Hospital, Yonsei University Health System, Seoul

Asan Medical Center - Oncology, Seoul

Samsung Medical Center - Hematology-Oncology, Seoul

NHS Greater Glasgow & Clyde - CRUK Clinical Trials Unit, Glasgow

Royal Liverpool Hospital [Hematology/Transfusion Medicine], Liverpool

Christie Hospital NHS Foundation Trust, Manchester